Jeppe Ragnar Andersen
Education:
University of Copenhagen - M.Sc., Pharmacy
Smartly School of Business - MBA
Jeppe Ragnar Andersen joined Nordic Bioscience in 2007 and became Head of Clinical Development in 2010. Jeppe was the CEO of NBCD A/S from 2014-2022, and has now transitioned into the position as Group CEO of Sanos Group A/S.
Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.
He has headed the successful merging of two clinical development departments and an expansion of the department with highly motivated employees from 3 employees to 30 employees.
University of Copenhagen - M.Sc., Pharmacy
Smartly School of Business - MBA
Jeppe Ragnar Andersen joined Nordic Bioscience in 2007 and became Head of Clinical Development in 2010. Jeppe was the CEO of NBCD A/S from 2014-2022, and has now transitioned into the position as Group CEO of Sanos Group A/S.
Jeppe is actively doing research into clinical trial methodology with a special focus on implementing risk-based monitoring and cost-benefit optimization. Over the years, Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within the therapeutic fields of osteoporosis, osteoarthritis and diabetes.
He has headed the successful merging of two clinical development departments and an expansion of the department with highly motivated employees from 3 employees to 30 employees.